{"prompt": "['71', 'MC1488 WEE1', 'MCCC', 'Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards', 'for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International', 'Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and', 'Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec', '15;21(24):4642-9. Erratum in: J Clin Oncol. 2004 Feb 1;22(3):576 LoCocco, Francesco', '[corrected to Lo-Coco, Francesco]. PubMed PMID: 14673054.', 'Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de', 'Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical', 'application and proposal for modification of the International Working Group (IWG) response', 'criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419-25.', 'Costantino D, Lowe L, Brown DL, et al (2006) Basosquamous carcinoma- an under-recognized, high-risk', 'cutaneous neoplasm: case study of the literature. J Plast Reconstr Aesthet Surg; 59:424-8.', 'Daya-Grosjean L, Couve-Privat S (2005) Sonic hedgehog signaling in basal cell carcinomas. Cancer', 'Letter; 225:181-192.', 'De Rie MA, Skvara H, Mickel L et al (2010) A double-blind, randomized, vehicle-controlled proof of', 'concept study to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics', 'of multiple topical administrations of LDE225 (a specific Smoothened inhibitor) on skin basal', 'cell carcinomas in Nevoid Basal Cell Carcinoma Syndrome (NBCCS) patients. Poster', 'presentation at SID (05-08 May2010); 524 Abstract.', 'Decker S. et al., Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for', 'Hedgehog-inhibitor responsiveness in CLL. Blood. 2012 Jan 26;119(4):997-1007. Epub', '2011 Nov 30.', 'Detmer, K. et al. Hedgehog signaling and cell cycle control in differentiating erythroid', 'progenitors. Blood Cells Mol Dis 34, 60-70, (2005).', 'Didier C, Cavelier C, Quaranta M, Galcera MO, Demur C, Laurent G, Manenti S, Ducommun B. G2/M', 'checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress.', 'Oncogene. 2008 Jun 19;27(27):3811-20', 'Dimitrova DS, Gilbert DM. Temporally coordinated assembly and disassembly of replication forks in the', 'absence of DNA synthesis. Nat Cell Biol. 2000;2(10):686-94.', 'Do K, Doroshow JH, Kummar S. Weel kinase as a target for cancer therapy. Cell Cycle. 2013 Oct', '1;12(19):3159-64.', 'Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS. Poor outcome of', 'patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma', 'Myeloma Leuk. 2013 Dec;13(6):711-5.', 'Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid tumours:', 'revised RECIST guideline (version 1.1). Eur J Cancer;45: 228-247', 'Emanuel RM et al., Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total', 'Symptom Score: Prospective International Assessment of an abbreviated Symptom Burden', 'Scoring System Among Patients With MPNs. J Clin Oncol. 2012 Oct 15. [Epub ahead of']['72', 'MC1488 WEE1', 'MCCC', 'print]', 'Evans M, Rees A (2002) Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the', 'same.Drug Saf 25 (9) 649-63', 'Fayers PM, Aaronson NK, Bjordal K et al. (2001) The EORTC QLQ-C30 Scoring Manual (3rd Edition).', 'European Organisation for Research and Treatment of Cancer.', 'Fenaux P, Mufti GJ, Hellstr\u00f6m-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore', 'S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR.', 'Azacitidine prolongs overall survival compared with conventional care regimens in elderly', 'patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb', '1;28(4):562-9.', 'Flockhart DA. (2007). Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University', 'School of Medicine, Version 5.0 released on January 12, 2009 (Internet) Available from:', '<http://medicine.iupui.edu/flockhart/table.htm> (Accessed 30 Nov 2010)', 'Food and Drug Administration (FDA) (2006). Guidance for Industry, Drug Interaction Studies - Study', 'Design, Data Analysis and Implications for Dosing and Labeling, Center for Drug Evaluation and', 'Research (CDER), Draft Guidance (Internet) Available from:', '<http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteracti', 'onsLabeling/ucm080499.htm> (Accessed 30 Nov 2010', 'Gailani MR, StahleBackdahl M, Leffell DJ, et al (1996) The role of the human homologue of Drosophila', 'patched in sporadic basal cell carcinomas. Nature Genetics; 14: :78-81.', 'Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W,', 'Pardanani A, Cervantes F, Passamonti F, Tefferi A. DIPSS plus: a refined Dynamic International', 'Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information', 'from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 Feb 1;29(4):392-7.', \"Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating\", 'M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage', 'therapy. Cancer. 2005 Aug 1;104(3):547-54.', 'Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res. 1998;72:197-233.', 'Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier', 'D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for', 'evaluating prognosis in myelodysplastic syndromes. Blood. 1997 Mar 15;89(6):2079-88.', \"Jabour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H.\", 'Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer.', '2010 Aug. 15; 116(16):3830-4.', 'Johns D, Andersen JS (1999) Use of Predictive probabilities in Phase II and Phase III Clinical trials.', 'Journal of Biopharmaceutical Statistics; 9:67-79', 'Kang HN et al, Abrogation of Gli3 expression suppresses the growth of colon cancer cells via', 'activation of p53. Exp Cell Res. 2012 Mar 10;318(5):539-49. Epub 2011 Dec 27.']\n\n###\n\n", "completion": "END"}